Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MASP2 | O00187 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975335 | 0.90 | ALDH1A1 (0.48) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19975248 | 0.85 | ALDH1A1 (0.41) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL21183521 | 0.83 | MAPK1 (0.42) | KMT2AMASP2RXFP1ALDH1A1GAA | |
| SCHEMBL19975126 | 0.80 | ALDH1A1 (0.47) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19974899 | 0.80 | MAPK1 (0.47) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19974811 | 0.79 | MASP2 (0.47) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19975435 | 0.78 | MASP2 (0.46) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19975379 | 0.77 | ALDH1A1 (0.51) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19975405 | 0.77 | MASP2 (0.49) | KMT2AMASP2RXFP1ADAM17ALDH1A1 | |
| SCHEMBL19975564 | 0.76 | MASP2 (0.48) | KMT2AMASP2RXFP1ADAM17ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | KMT2A 4031/4885MASP2 1122/4885RXFP1 1779/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | KMT2A 4177/4885MASP2 862/4885RXFP1 2251/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | KMT2A 4031/4885MASP2 1122/4885RXFP1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.